"Those different creative combinations are...

 ...helping the market become more dynamic. Then we’ll see who can walk and who will fall — that’s just how the market works….they’re all promising at this point, but they’ll face significant risk. And only time can tell what is the best model."

— Ge Bai, Ph.D., a professor at Johns Hopkins University’s schools of public health and business, spoke with AIS Health’s Radar on Drug Benefits about two new PBM startups, EmsanaRx and CostPlus PBM, and their odds for success.

 

Subscribers may read the RADAR on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.